Pancreatic Cancer Research

ResearcherUniversity of RochesterActive in the last 2 years

Stephano S. Mello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2484-086X; OpenAlex author ID A5074529193. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 7

  1. UNC5B regulates epithelial-to-mesenchymal transition through a SRC-ZEB1 signaling axis to facilitate pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03908-4↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  3. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  4. Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation Last author DOI 10.1101/2024.05.29.595146↗
  5. Multifaceted role for p53 in pancreatic cancer suppression. Co-author DOI 10.1073/pnas.2211937120↗
  6. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.09.007↗
  7. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laura D Attardi · 5 shared papers, 2015–2026 · strength 0.59
  2. Pawel Karol Mazur · 4 shared papers, 2015–2026 · strength 0.54
  3. Marija Trajkovic‐Arsic · 3 shared papers, 2015–2026 · strength 0.37
  4. Mert Erkan · 3 shared papers, 2015–2026 · strength 0.37
  5. Bence Sipos · 3 shared papers, 2015–2026 · strength 0.37
  6. Julien Sage · 3 shared papers, 2015–2026 · strength 0.37
  7. Irina Heid · 3 shared papers, 2015–2026 · strength 0.37
  8. Stephan A. Hahn · 3 shared papers, 2015–2026 · strength 0.37
  9. Alexander Herner · 3 shared papers, 2015–2026 · strength 0.37
  10. Roland Michael Schmid · 3 shared papers, 2015–2026 · strength 0.37
  11. Jens Thomas Siveke · 3 shared papers, 2015–2026 · strength 0.37
  12. Iréne Esposito · 3 shared papers, 2015–2026 · strength 0.37
  13. Elisabeth Heßmann · 3 shared papers, 2015–2026 · strength 0.37
  14. Jorg H. Kleeff · 3 shared papers, 2015–2026 · strength 0.37
  15. Simone Hausmann · 3 shared papers, 2015–2026 · strength 0.37
  16. Rickmer Braren · 3 shared papers, 2015–2026 · strength 0.37
  17. Matthias Wirth · 3 shared papers, 2015–2026 · strength 0.37
  18. Volker Ellenrieder · 3 shared papers, 2015–2026 · strength 0.37
  19. Tyler Jacks · 3 shared papers, 2015–2026 · strength 0.37
  20. Muhammad Sadeqi Nezhad · 1 shared paper, 2026 · strength 0.25
  21. Aram F. Hezel · 1 shared paper, 2026 · strength 0.25
  22. Darren R. Carpizo · 1 shared paper, 2026 · strength 0.25
  23. Jennifer J. Twardowski · 1 shared paper, 2024 · strength 0.24
  24. Brittany M. Flowers · 2 shared papers, 2017–2023 · strength 0.22
  25. Laura DeLong Wood · 2 shared papers, 2017–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.